InSyBio Harnesses the Power of Clinical Data developing AI tools for Cardiovascular Disease Treatment Optimization

Cardiovascular diseases (CVDs) are the leading cause of death globally, with 17.9 million annual deaths. InSyBio has partnered with Syndesis, the data and technology catalyst to a truly global, multi-continent network of healthcare and life sciences organizations, to address this enormous global health issue.

We focused on two specific heart diseases, congestive heart failure (CHF) and hypertrophic cardiomyopathy (HCM). Congestive heart failure (CHF), or heart failure, is a long-term condition characterized by the inability of the myocardium to meet the body’s blood supply needs. Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease that causes alterations in heart’s structure. It is associated with high mortality due to sudden cardiac arrest and frequently requires heart transplant. When faced with patients suffering from CHF or HCM, doctors are often challenged in ensuring the optimal therapeutic protocol that reduces the risk of dangerous complications or death.

Existing clinical scores (Qrisk2, SCORE, Framingham) perform poorly in predicting 5-year mortality and short-term outcome (<60% Area Under the Curve, AUC) in both disease areas. Artificial Intelligence can provide significant support in such clinical decisions, by predicting outcomes for patients based on certain therapeutic protocols.

PrecisionCHF and PrecisionHCM

InSyBio analyzed a highly curated cardiovascular data set using Syntium, Syndesis Health’s data platform of anonymized clinical data, in order to develop two Precision Medicine Tools based on Artificial Intelligence. These tools predict CHF and HCM risk and can help to reduce it by recommending changes to the therapeutic protocol of the patients suffering from these diseases.

The AI tools – “PrecisionCHF” and “PrecisionHCM” – were trained on data from 1044 patients hospitalized with Congestive Heart Failure (CHF) and 255 Hypertrophic cardiomyopathy (HCM) patients with full clinical annotation and outcomes mined from Syntium.

Following training on the data, the AI tools performed impressively well: PrecisionCHF was able to predict 5-year mortality for CHF with 75% AUC, while PrecisionHCM was able to predict short term outcome (i.e. mortality until discharge) with 97% AUC. Using the AI tools 37% of CHF and 28% of HCM patients at risk can substantially reduce their risk (>5% reduction) with the optimization of their medication plan. Moreover, 12% of the rest of CHF and 11% of the rest of HCM who are not at risk can further reduce their risk by at least 5%.

The collaboration between InSyBio and Syndesis has demonstrated the enormous value of training AI pipelines for medical applications using relatively “small” but highly curated and validated clinical data, and the importance of innovative platforms such as InSyBio Diagnostics Platform and Syntium.

These tools can be accessed via the newly launched InSyBio Diagnostics Platform:

About InSyBio. InSyBio is an international pioneer biotechnology company revolutionizing the medical field through targeted biomarker discovery, highly accurate predictive analytics and the development of personalization tests for drugs. Its solutions provide the R&D departments of Pharma and Research Institutes with the means to meet their most challenging research and innovation goals. This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics and clinical data, thus reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals, and research centres allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and a decrease of at least 80% in overall time and cost.

Scroll to top